Objectives: To assess the long term effects of small increases in dietary folic acid on the concentration of plasma homocysteine, an independent risk factor for occlusive vascular disease, in a general population. Design: A randomized double-blind placebo-controlled intervention study. Subjects: One hundred and nineteen healthy volunteers, whose intake of forti®ed or supplemental folic acid was low, were recruited by letter from the patient register of a large inner-city group general practice. Methods: Volunteers were randomized to receive unforti®ed cereals, or cereals forti®ed with 200 mg of folic acid per portion, with or without other vitamins. Blood samples were taken presupplement and at 4, 8 and 24 weeks on treatment and analysed for plasma homocysteine, cysteine and vitamin B12 and serum and red cell folate. Ninety-four subjects completed the study providing blood samples on all four occasions.
Introduction
There is now considerable evidence that hyperhomocysteinaemia is an independent risk factor for occlusive vascular disease (OVD) (Pancharuniti et al, 1994; Brattstro Èm et al, 1992; Stampfer et al, 1992; Clark et al, 1991; Verhoef et al, 1996) . Whilst patients with inherited forms of homocysteinaemia have the highest risk, ®ndings suggest that much lower levels of plasma homocysteine than are found in the homozygous condition are a risk factor for stroke, and for peripheral vascular and ischaemic heart disease (Boushey et al, 1995; Nygard et al, 1997) . The evidence has been reviewed and is remarkably consistent (Malinow, 1990; Ueland et al, 1992; Boers, 1994; Masser et al, 1994) with those at most risk appearing to be at the upper end of the normal population range for plasma homocysteine (b14 mmol/L) (Israelsson et al, 1988; Brattstro Èm et al, 1992; Jacobson et al, 1994; Selhub et al, 1996) . It is, as yet, unknown whether plasma homocysteine is a causative risk factor for OVD, but increasing evidence suggests that it is (Taylor et al, 1991; Stampfer et al, 1992; Boushey et al, 1995) .
However, unlike plasma cholesterol, which often responds poorly to dietary manipulation, plasma homocysteine is inversely associated with and can be decreased by increased intakes of vitamins, such as B6 and B12, and especially folic acid (Pancharuniti et al 1994; Bergmark et al, 1993; Masser et al, 1994; Selhub et al, 1996; Verhoef et al, 1996) . Folic acid is very effective, with pharmacological doses (b1 mg/d) able to reduce plasma homocysteine levels even when these are within the population reference range (Brattstro Èm et al, 1985; Olszcwski et al, 1989; Wilcken et al, 1988; Israelsson et al, 1988; Boers, 1994; Arnadottir et al, 1993) . To date no population studies have investigated if physiological increases in folic acid intake, within the range which could be achieved by improvements in the diet or the use of forti®ed foods, can affect plasma homocysteine. It is also unclear whether any effect of folate can be sustained long term. Such studies are crucial. Should current intervention programmes show that hyperhomocysteinaemia is a causative risk factor for OVD, then folic acid forti®cation of staple foods would be an ideal approach to OVD prevention, as is the case with folate prevention of neural tube defects (Schorah & Wild, 1993) . Although it is very unlikely that high dose folic acid would be used to fortify foods, because of potential harm such intakes may cause (Chanarin, 1994) , the inverse relationship between serum folate and homocysteine concentrations within the physiological range suggests that homocysteine may well respond to small increases in folate intake (Begmark et al, 1993; Masser et al, 1994; Pancharuniti et al, 1994; Selhub et al, 1996; Verhoef et al, 1996) .
We have, therefore, conducted a population study in a domiciliary setting to see whether food forti®ed with folic acid at physiological levels, re¯ecting the UK reference nutrient intake (RNI), can reduce plasma homocysteine, not only in the short term, but over an extended period.
Materials and methods

Subjects
Healthy volunteers, who were not consuming vitamin supplements or breakfast cereals and who would, therefore, be receiving negligible forti®ed or supplemental intake of folic acid, were recruited by questionnaire from subjects registered with a large inner-city group general practice in Leeds. In addition to signi®cant concurrent disease, the only other exclusions were age`18 y or b80 y, and pregnancy. All participants gave informed consent and the study was approved by the local ethics committee. Volunteers were randomized double blind to one of three arms: (i) cereals forti®ed with folic acid (pteroylmonoglutamic acid) at 666 mg/100 g (approximately 200 mg/portion); (ii) cereals forti®ed with this same concentration of folic acid plus the usual level of other vitamin forti®cation of the cereal (thiamine, 1.2 mg; ribo¯avin, 1.3 mg; niacin, 15 mg; pyridoxine, 1.7 mg; vitamin B12, 0.85 mg; vitamin C, 50 mg; vitamin D, 4.2 mg/100 g cereal); (iii) unforti®ed cereals. All three formulations contained supplemental iron at 7.9 mg/100 g. Fasting blood samples were taken immediately before the cereals were issued, and the blood samples repeated at 4, 8 and 24 weeks. Patients were encouraged to eat one portion of cereals each day throughout the period of the study. One hundred and nineteen patients initially entered the study and 94 of these provided blood samples on all four occasions. It is results on the 94 patients completing the study that are presented here.
Analyses
Blood samples were taken into lithium heparin for plasma homocysteine and cysteine, and plain and EDTA tubes for serum and red cell folate and vitamin B12, and prepared immediately for analysis with subsequent storage at 720 C for the vitamins and 780 C for plasma thiols. Total homocysteine and cysteine were analysed by HPLC with¯uorescence detection following derivatization (Daskalakis et al, 1996) . Folate and B12 were measured using a commercial radio-assay (Diagnostic Products Corporation). Samples from the same person were analysed at different times, and the between batch precision (CV%) of the technique was 2.5% for homocysteine, 3.5% for cysteine, 10% for serum and red cell folate and 9% for B12.
The biochemical data were not normally distributed, so data analysis was by non-parametric techniques: Kruskal± Wallis for one way analysis of variance; Wilcoxon±Mann± Whitney U for unpaired comparisons between treatments, and Wilcoxon matched-pairs signed-rank test for paired changes within treatment groups.
Results
One way analysis of variance by treatment group on the initial values of the 94 patients who completed the study showed that there were no signi®cant pre-treatment differences between the three treatment groups for age and concentrations of serum and red cell folate, homocysteine, cysteine and vitamin B12 (Table 1 ). The data distribution of the measured indices is typical of a normal population. The randomization did generate some small sex differences between the groups (proportion of males were 40, 52, 58%: Homocysteine mmol/L 0 10.4 (7.8 ± 12) 10.2 (8.2 ± 11.7) 11.0 (8.3 ± 12.7) 4 10.9 (8.5 ± 11.4) 9.6 (8.2 ± 10.6) b 10.6 (8.2 ± 12.2) 8 11.0 (7.9 ± 12) 9.4 (8.0 ± 11.6)* b 9.9 (8 ± 11)** b 24 10.8 (8.5 ± 12.6) 9.1 (7.6 ± 9.9)** c 10.1 (7.4 ± 12.5) placebo, folic acid, multi-vitamin groups respectively) but this did not lead to any initial differences in the parameters measured.
Overall treatment effects, as measured by difference between the pre-treatment value and the values at all of the three time points during treatment, were signi®cant for homocysteine, serum folate and red cell folate, (P`0.001) but not for vitamin B12 and cysteine. Analysis of variance at the individual time points showed that the treatment effects on serum folate were signi®cant at 4 weeks (P`0.001), 8 weeks (P`0.05) and 24 weeks (P`0.001) and for homocysteine at 8 weeks and 24 weeks (P`0.05), but red cell folates were not signi®cantly different from the initial values until the 24th week (P`0.001). There were no signi®cant treatment effects on vitamin B12 or cysteine at any time point. Analysis of data by individual treatments (Table 1) showed that the overall treatment effect was due to a similar response in the two folic acid containing regimens, which both signi®-cantly increased serum folate and reduced homocysteine, with the placebo arm having no signi®cant effect on these parameters (Wilcoxon matched-pairs signed-rank test). The changes on treatment in the folic acid groups were signi®cantly different from those in the placebo group for serum folate at 4, 8 and 24 weeks, and for homocysteine at 8 and 24 weeks, but treatment effects in the two folate groups were not signi®cantly different from each other for any analyte at any time point (Wilcoxon±Mann±Whitney U test on the differences, Table 1 ).
Further analysis of the pooled results of the two folate treatment groups (Table 2) showed that the folate effect on homocysteine was primarily in those who began the study with the lowest serum folate levels. In addition, folic acid supplementation did not affect homocysteine in those whose initial levels for this amino acid were in the lowest tertile of the range (Table 2) .
Discussion
Previous studies that have employed relatively low doses of folic acid have used either small numbers or specialised population groups with hyperhomocysteinemia to demonstrate the impact on homocysteine of increased folic acid intake (Ubbink et al, 1994; Guttormsen, 1996; Ward et al, 1997) . This is the ®rst time a general practice population has been used for such a study and the ®ndings are thus important in terms of the developing policy debate about folate forti®cation and the prevention of OVD. The results show that consumption of up to an extra 200 mg/d of folic acid, delivered through a forti®ed breakfast cereal, with or without other vitamins, has led to a signi®cant increase (66%) in serum folate which precedes an increase in red cell folate. This is as expected because red cell levels do not respond to dietary change until a new population of erythrocytes has been released from the bone marrow (approximately 3 ± 4 months).
It is dif®cult to be precise about compliance in a population study such as this, but we have reason to believe that it was good. All subjects who completed the study regularly collected fresh supplies of cereals from the practice, indicating consumption, and the medium rise in red cell folate by the end of the study in the supplemented groups (126 mg/L) was similar to that (164 mg/L) recorded by Daly et al (1997) where 200 mg of folic acid was administered in tablet form and carefully monitored.
The increase in blood folate in the two folic acid treatment groups is associated with a small but signi®cant decrease in homocysteine (10%). The addition of other vitamins, such as B6 and B12 which are known to be implicated in the conversion of homocysteine to cystathionine and methionine respectively (Boers, 1994) and hence to have a potential role for lowering plasma homocysteine levels, did not, however, add to the folate effect (Table 1) . The increased intake achieved by the supplemented as opposed to the placebo cereal for vitamin B6 and B12 was 40% and 20% of the RNI respectively (Department of Health, 1991). In contrast, folic acid was provided at 100% of its RNI. It could therefore be argued that less of a homocysteine response would be expected from B6 and B12, especially as other studies have indicated that they are not as closely associated as folate with lower plasma homocysteine, particularly when levels of these vitamins are within the normal reference range (Ubbink et al, 1994; Verhoef et al, 1996; Selhub et al, 1996) .
Homocysteine appears to be similar to cholesterol, in that there is, as yet, no known threshold for the atherogenicity of this amino acid, so that the higher the plasma homocysteine the greater risk, even within the normal reference range (Boushey et al, 1995; Nygard, 1997) . Hence, the importance of the ®ndings of this primary care study which show that the higher the initial homocysteine, the greater the folate effect, even with relatively small increases in folic acid intake. Published work also indicates that there is a decrease in the slope of the inverse relationship between homocysteine and serum folate when folate concentrations are in the upper half of the reference range (Molgaard et al, 1992; Lewis et al, 1992; Selhub et al, 1993; Jacobsen et al, 1994; Pancharuniti et al, 1994) . This bimodal inverse relationship is con®rmed here, as the plasma homocysteine decrease following supplementation Homocysteine responsiveness to folate CJ Schorah et al was largely con®ned to those who were initially within the lower tertile of the serum folate range ( Table 2 ). The upper limit of this lower tertile was 6.6 mg/L. By week 24, 48% of the placebo groups remained below this value, but only 8% of those supplemented with folic acid. Clearly the consumption of cereals forti®ed with a low dose of folic acid, has enabled the majority of subjects to move out of the range of serum folates where the frequency of high plasma homocysteine values is greatest.
Conclusions
This study in a primary care setting has shown that forti®cation of food with folic acid at the RNI (200 mg/d) is capable of increasing serum folate levels substantially, and having some long term impact on plasma homocysteine, especially in those with the highest initial levels. Hence, if homocysteine is found to be a causative risk factor for OVD, food forti®cation would be an effective way of having a signi®cant impact on the prevalence of the disease at the population level. The observed increase in blood folate would also have a signi®cant impact on the prevention of neural tube defects as following supplementation over 75% of subjects receiving folate had red cell folates greater than the 400 mg/L, the threshold which Daly et al (1997) believe achieves maximum protection against this malformation. However, because the average fall in homocysteine has been relatively small, individuals with plasma homocysteine concentrations greater than the upper limit (97.5th centile) of the reference values for this amino acid (b20 mmol/L in this study), would possibly also need to take folic acid at higher levels in order to encourage a more dramatic decline in their especially high homocysteine concentrations (Guttormsen et al, 1996) . These higher intakes of folate (b1 mg) are unlikely to be recommended for all because of the potential masking of pernicious anaemia (Chanarin, 1994) . Whilst this concern has almost certainly been greatly exaggerated (Dickinson, 1995) , the remote possibility of harm has affected folate forti®cation policy with regard to the prevention of NTD in the USA, where forti®cation is limited to increasing average intake by 100 mg/d, although much more would be needed to maximise prevention (Oakley et al, 1996) , and in Britain where we still have no policy for mandatory folate forti®cation of food in spite of the need for it (Schorah & Wild, 1993) . There is therefore an urgent requirement for further research in this area to determine the most effective modi®cations to diet and food policy.
